Inhibikase Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Inhibikase Therapeutics

16/08/2021 23:38

* Inhibikase Therapeutics Inc  IKT.OQ  reported a quarterly
adjusted loss of 22 cents​​ per share for the quarter ended in
June. The lone analyst forecast for the quarter was for a loss
of 38 cents per share.
* Revenue was $1.36 million​;  analysts expected $300.00
thousand. 
* Inhibikase Therapeutics Inc's reported EPS for the quarter was
a loss of 22 cents​.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Inhibikase Therapeutics Inc shares had fallen by 31.8% this
quarter and lost 72.3% so far this year.
* The company reported a quarterly loss of $2.64 million.
* Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $13.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 16 at 10:38 p.m.  ​All
figures in US dollars unless otherwise stated